- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Progynova - estrogen.
Fills the lack of endogenous estrogen, lowers LDL cholesterol in the blood. Suppresses somatic, mental and other climacteric symptoms during periods of pre- and postmenopause, or after oophorectomy; prevents bone loss and osteoporosis.
Estrogen deficiency (postmenopausal period, oophorectomy, radiation castration), accompanied by vasomotor symptoms: hot flashes, sweating, sleep disturbances, depressive states, irritability, headache, dizziness, hyperesthesia of the bladder, degenerative changes of the skin and mucous membranes; prevention of osteoporosis.
1 tablet contains:
Active substance: estradiol valerat2 mg;
Excipients: lactose monohydrate 46-250 mg; corn starch 26 to 200 mg; Povidone 25,000 - 3 mg; talc - 2.4 mg; magnesium stearate - 0.15 mg; crystalline sucrose 33 - 540 mg; Povidone 700000 - 0.323 mg; macrogol 6000 - 3,719 mg; calcium carbonate precipitated 14 - 572 mg; talc - 7,104 mg; glycerol 85% (w / w) - 0.205 mg; titanium dioxide (E171, C.1.77891) - 0.411 mg; Indigo Carmine (E132, C.1.73015) - 0.051 mg; montaglycol wax - 0.075 mg.
Estradiol is marketed under different brands and generic names, and comes in different dosage forms:
|Brand name||Manufacturer||Country||Dosage form|
|Proginova||Bayer Pharma AG||Germany||dragee|
|Climara® (Bayer Pharma AG||Bayer Pharma AG||Germany||transdermal therapeutic system|
No customer reviews for the moment.
Dosage and Administration
Inside The tablet should be swallowed whole, without chewing, with a sufficient amount of water.
Classification of the incidence of side effects of the World Health Organization (WHO):
very often - 1/10 of appointments (> 10%)
often from 1/100 to <1/10 of appointments (> 1% and
infrequently - from 1/1000 to 0.1% and
rarely from 1/10000 to 0.01% and
very rarely — astrota is unknown — cannot be estimated based on available data.
In each group, unwanted effects are presented in order of decreasing severity.
Nervous system disorders
Infrequently: drowsiness, sleeplessness, dizziness, paresthesias.
Seldom: excitement, confusion, depression.
Very rarely: aggressive behavior, hallucinations.
Disorders of the digestive system
Often: abdominal pain, diarrhea, flatulence, nausea, vomiting, constipation.
Infrequently: dry mouth, increased activity of "liver" enzymes.
Rarely: stomatitis, gastrointestinal candidiasis (GIT), hepatitis (with or without jaundice).
Very rare: liver failure, hepatic encephalopathy in patients with a history of liver disease, microscopic colitis.
Kidney and urinary tract disorders
Very rare: interstitial nephritis.
Frequency unknown: renal failure.
Reproductive system disorders
Very rare: gynecomastia.
Violations of the musculoskeletal system
Rarely: arthralgia, myalgia.
Very rare: muscle weakness.
Frequency unknown: fractures of the femoral neck, wrist bones, vertebrae.
Violations of the skin
Infrequently: itch, rash, urticaria, dermatitis, peripheral edema.
Rarely: alopecia, photosensitivity, malaise, excessive sweating.
Very rarely: Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme.
Disorders of the blood-forming organs
Rarely: leukopenia, thrombocytopenia.
Very rare: agranulocytosis, pancytopenia.
Violations of the sense organ
Infrequently: blurred vision.
Rarely: a violation of taste.
Rarely: hypersensitivity reactions (eg, fever, angioedema, anaphylactic reaction / anaphylactic shock).
Laboratory and instrumental data
Very rarely: hypomagnesemia, hypocalcemia due to severe hypomagnesemia, hypokalemia due to severe hypomagnesemia.
- Hypersensitivity to esomeprazole, substituted benzimidazoles or other components of the drug;
- Children's age up to 12 years (due to the lack of data on the efficacy and safety of the drug in this group of patients);
- Children's age from 12 to 18 years old by all indications, except GERD;
- Simultaneous reception with atazanavir and nelfinavir.
Severe renal failure (experience of use is limited).
Pregnancy and Lactation
There are currently insufficient data on the use of esomeprazole during pregnancy. The results of epidemiological studies of esomeprazole, which is a racemic mixture, showed no fetotoxic effect or impaired fetal development. In animal studies, no direct or indirect adverse effect on the development of the embryo or fetus was found, both with the administration of esomeprazole and with the administration of the racemic mixture. Pregnant women should be prescribed only if the expected benefit to the mother outweighs the potential risk to the fetus. It is not known whether esomeprazole is excreted in breast milk, so the drug should not be used during breastfeeding
Currently, cases of overdose of the drug esomeprazole are described extremely rarely.Oral administration of esomeprazole at a dose of 280 mg was accompanied by general weakness and symptoms of the gastrointestinal tract. Single dose of 80 mg of esomeprazole did not cause any negative effects.
Treatment: The specific antidote is unknown. Hemodialysis is ineffective. In case of overdose, symptomatic and general maintenance therapy is recommended.
- Brand name: Esomeprazole
- Active ingredient: Esomeprazole
- Manufacturer: Canonpharma
- Country of Origin: Russia
- Investigation of the alteration of the composition of various essential oils used in aroma lamp applications
- Composition of the Essential Oils of Commercial Samples of Salvia officinalis L. and S. fruticosa Miller: A Comparison of Oils Obtained by Extraction and Steam Distillation
- Chemical composition of essential oils from some Salvia species
- Composition of the essential oils from leaves and fruits of three Hedyosmum species from Costa Rica
- Thrombotic thrombocytopenic purpura and 17β-estradiol transdermal skin patch
- Potentiation of antitumor activity of mitomycin C by estradiol: Studies of human breast carcinoma xenografts serially transplanted into nude mice
- Estradiol increases the frequency of multiple synapse boutons in the hippocampal CA1 region of the adult female rat
- Reflection contrast microscopy for high resolution detection of3H-estradiol in ultrathin sections of human stratum corneum
- Human prostatic smooth muscle cells in culture: Estradiol enhances expression of smooth muscle cell-specific markers
- Effect of combined testosterone and estradiol-17β treatment on the metabolism of E2 in the prostate and liver of noble rats
- Pretreatment plasma testosterone and estradiol levels in patients with locally advanced or metastasized prostatic cancer
- Estradiol-17β stimulates aromatase activity and reversible sex change in protandrous black porgy,Acanthopagrus schlegeli
- Response of diencephalon but not the gonad to female-promoting temperature with elevated estradiol levels in the sea turtleLepidochelys olivacea
- Changes in body weight, ovarian growth, and circulating plasma estradiol level in response to programmed photoperiods in blackheaded bunting,Emberiza melanocephala
- Evidence of a progesterone receptor in the liver of the green frogRana esculenta and its down-regulation by 17? estradiol and progesterone
- Ultrastructure of the uterus in an ovariectomized gecko (Hemidactylus turcicus) after administration of exogenous estradiol
- Monte Carlo-minimized energy profile of estradiol in the ligand-binding tunnel of 17β-hydroxysteroid dehydrogenase: Atomic mechanisms of steroid recognition
- Neonatal exposure of male rats to estradiol benzoate causes rete testis dilation and backflow impairment of spermatogenesis
- A 67 kDa non-hormone binding estradiol receptor is present in human mammary cancers
- Modulation of lymphokine-activated killer cell-mediated cytotoxicity by estradiol and tamoxifen
- Antagonism between estradiol and progestin on Bcl-2 expression in breast-cancer cells
- Concentrations of estrone, estradiol and their sulfates, and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma
- Estradiol and fibulin-1 inhibit motility of human ovarian- and breast-cancer cells induced by fibronectin
- Laminin and estradiol regulation of the plasminogen-activator system in MCF-7 breast-carcinoma cells